Clinical Trials
10 trialsNCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT05228015 2024-11-18
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT02707666 2024-07-31
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Phase 1 Terminated
NCT04042480 2023-03-23
A Study of SGN-CD228A in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT04173338 2022-06-14
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
Phase 1 Terminated
NCT01143545 2020-03-03
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00094978 2019-12-12
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01445392 2018-08-03
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02372227 2017-01-30
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
Phase 1 Terminated